Personalized Medicine Biomarkers Market Size, Share and Trends Report 2025 to 2034
Global Personalized Medicine Biomarkers Market Size is valued at USD 22.9 Bn in 2023 and is predicted to reach USD 59.1 Bn by the year 2031 at an 12.8% CAGR during the forecast period for 2024 to 2031.
Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Distribution by Type (Genetic Biomarkers, Protein Biomarkers, Metabolite Biomarkers), By Application (Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Others), By End User (Hospitals, Diagnostic Laboratories, Research Institutions) and Segment Forecasts, 2024 to 2031
The Personalized Medicine Biomarkers Market is a continuously developing area of healthcare focused on using biomarkers, which are biological markers such as proteins or genetic mutations for individualized treatments. Thus, these biomarkers are useful in all the stages involved in healthcare, starting from preliminary detection of the disease till proper diagnosis, selection of treatment, and monitoring. This approach is aligned with the patient's unique biological profile and, therefore, increases the therapeutic outcomes while minimizing the potential side effects in fields such as oncology, cardiology, and autoimmune diseases.
The key drivers of this market are the increasing incidence of chronic diseases such as cancer, cardiovascular conditions, and diabetes that require more accurate diagnostic and therapeutic solutions. Further, advancements in genomics and proteomics are accelerating the discovery and application of new biomarkers, increasing our understanding of disease mechanisms. These are also revolutionizing drug development, with the identification of appropriate candidates for clinical trials and improved stratification of patients for targeted therapies.
Competitive Landscape
Some of the Key Players in Personalized Medicine Biomarkers Market:
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Foundation Medicine, Inc.
- Genomic Health, Inc
- Guardant Health, Inc.
- Illumina, Inc.
- Luminex Corporation
- Merck KGaA
- Myriad Genetics, Inc
- QIAGEN N.V
- Roche Diagnostics
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
- Coriell Life Sciences.
- Laboratory Corporation of America Holding
- NeoGenomics Laboratories
- Quest Diagnostics Incorporated
Market Segmentation:
The personalized medicine biomarkers market is segmented by type, application, end user. By type the market is segmented into genetic biomarkers, protein biomarkers, metabolite biomarkers. By application the market is categorized into oncology, neurology, diabetes, autoimmune diseases, cardiology, and others. By end user the market is categorized into hospitals, diagnostic laboratories, research institutions.
Genetic Biomarkers is Expected to Drive the Personalized Medicine Biomarkers Market
The genetic biomarkers segment is a key driver of the Personalized Medicine Biomarkers Market, particularly in oncology, would be the genetic biomarkers segment where their value lies in finding the appropriate specific tumor mutations so that specific targeted therapies might be available for an individual patient for better treatment. The genomics technologies now include advancements in next-generation sequencing that have improved in the discovery of genetic mutations better for predictions related to disease susceptibility and regarding treatment responses. Further regulatory support for companion diagnostics based on genetic biomarkers spurs innovation and drives investment by pharmaceutical companies, fueling the growth of the market.
Oncology is Growing at the Highest Rate in the Personalized Medicine Biomarkers Market.
The Oncology segment is the fastest-growing application area in the Personalized Medicine Biomarkers Market, led by the increasing prevalence of cancer and the growing demand for biomarkers that predict patient responses to targeted therapies and immunotherapies. Cancer cases are expected to rise to 29.5 million by 2040, and the need for accurate diagnostic and therapeutic solutions is growing. Improvements in genomic technologies, including NGS, have transformed cancer diagnostics by allowing the precise determination of genetic mutations that indicate targeted therapy. Moreover, regulatory support from agencies, such as the FDA, which has approved many targeted cancer therapies, continues to further drive investment in biomarker R&D, which further establishes oncology's leadership.
Regionally, North America Led the Personalized Medicine Biomarkers Market.
North America is an influential region for the Personalized Medicine Biomarkers Market, mainly due to the presence of big names such as Thermo Fisher Scientific, Illumina, and Guardant Health, leaders in biotechnology that innovate research and development for biomarkers. Advanced healthcare infrastructure in the region along with the latest technologies, such as NGS and liquid biopsies, optimize biomarker identification and personalized treatment. Advances in genomic technologies are also underpinned by the rise in the demand for targeted therapies in the wake of rising chronic disease incidence, especially cancer. Substantial research funding in North America also ensures that collaborations among academic institutions and industry players create a great momentum for personalizing medicines.
Personalized Medicine Biomarkers Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 22.9 Bn |
| Revenue Forecast In 2031 | USD 59.1 Bn |
| Growth Rate CAGR | CAGR of 12.8% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Application, End User, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Foundation Medicine, Inc., Genomic Health, Inc, Guardant Health, Inc., Illumina, Inc., Luminex Corporation, Merck KGaA, Myriad Genetics, Inc, QIAGEN N.V, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific Inc., Coriell Life Sciences, Laboratory Corporation of America Holding, NeoGenomics Laboratories, Quest Diagnostics Incorporated |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Personalized Medicine Biomarkers Market :
Personalized Medicine Biomarkers Market by Type -
- Genetic Biomarkers
- Protein Biomarkers
- Metabolite Biomarkers
Personalized Medicine Biomarkers Market by Application -
- Oncology
- Neurology
- Diabetes
- Autoimmune Diseases
- Cardiology
- Others
Personalized Medicine Biomarkers Market by End User -
- Hospitals
- Diagnostic Laboratories
- Research Institutions
Personalized Medicine Biomarkers Market by Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
The Personalized Medicine Biomarkers Market Size is valued at USD 22.9 Bn in 2023 and is predicted to reach USD 59.1 Bn by the year 2031
The Personalized Medicine Biomarkers Market is expected to grow at an 12.8% CAGR during the forecast period for 2024-2031.
Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Foundation Medicine, Inc., Genomic Health, Inc, Guardant Health, Inc., Illumina, Inc., Luminex
Type, Application, End User are the key segments of the Personalized Medicine Biomarkers Market
North American region is leading the Personalized Medicine Biomarkers Market.